Literature DB >> 35001332

Risk factors of pulmonary embolism in the elderly patients: a retrospective study.

Yuxia Ma1, Yi Liu2, Ying Zhi3, Haibin Wang3, Mei Yang3, Jieting Niu3, Li Zhao3, Pengsheng Wang3.   

Abstract

AIM: We aimed to summarize the clinical feature and risk factors of patients suffering from pulmonary embolism (PE) in the elderly patients, and explore the change in D-dimer after anti-coagulant therapy.
METHODS: A total of 426 patients with PE admitted from August 2012 to January 2019 in the Cangzhou Central Hospital were analyzed in this retrospective study. A comparison of clinical features and risk factors was conducted between the elderly group and non-elderly groups. Blood levels of D-dimer, C-reactive protein (CRP), tumor necrosis factor-α and interferon-γ were measured before and 3 days after anti-coagulant therapy in two groups.
RESULTS: The most important risk factor for the elderly patients was stroke, while for non-elderly patients was deep vein thrombosis (DVT). After anti-coagulant therapy, the decreasing level of D-dimer and CRP showed statistically significant differences between the two groups. Between the elderly and non-elderly groups, the main clinical manifestations were similar. The risk factors of elderly patients were chronic obstructive pulmonary disease, malignant tumor, DVT and stroke. After anti-coagulant therapy, the content of D-dimer was lower than 3 days ago.
CONCLUSION: Blood levels of D-dimer and CRP may be potent screening markers for PE especially among elderly patients.
© 2021. The Author(s), under exclusive licence to Springer Nature Switzerland AG.

Entities:  

Keywords:  Anti-coagulant; D-dimer; Pulmonary embolism; Risk factors; Stroke

Mesh:

Year:  2022        PMID: 35001332     DOI: 10.1007/s40520-021-02031-6

Source DB:  PubMed          Journal:  Aging Clin Exp Res        ISSN: 1594-0667            Impact factor:   3.636


  12 in total

Review 1.  Pulmonary embolism in the elderly.

Authors:  A R Berman
Journal:  Clin Geriatr Med       Date:  2001-02       Impact factor: 3.076

2.  LncRNA Expression Profiling in Advanced Resected Gastric Adenocarcinoma Tissues.

Authors:  Yuan Dang; Liying Lin; Xiaojuan Ouyang; Fan Zhang; Shaoquan Chen; Bing Wang; Zaizhong Zhang; Shuming Chen; Lin Deng; Wen Wang; Lie Wang; Chunhong Xiao; Yafeng Qi
Journal:  Clin Lab       Date:  2019-12-01       Impact factor: 1.138

Review 3.  Diagnosis and management of pulmonary embolism in the elderly.

Authors:  Helia Robert-Ebadi; Marc Righini
Journal:  Eur J Intern Med       Date:  2014-04-03       Impact factor: 4.487

Review 4.  Prevention of Deep Vein Thrombosis and Pulmonary Embolism in High-Risk Medical Patients.

Authors:  Megan McCullough; Cyrus Kholdani; Roham T Zamanian
Journal:  Clin Chest Med       Date:  2018-09       Impact factor: 2.878

Review 5.  Diagnosis and Exclusion of Pulmonary Embolism.

Authors:  Jeffrey A Kline
Journal:  Thromb Res       Date:  2017-06-07       Impact factor: 3.944

Review 6.  Pulmonary Embolism.

Authors:  Eno-Obong Essien; Parth Rali; Stephen C Mathai
Journal:  Med Clin North Am       Date:  2019-05       Impact factor: 5.456

Review 7.  Deep vein thrombosis and pulmonary embolism.

Authors:  Marcello Di Nisio; Nick van Es; Harry R Büller
Journal:  Lancet       Date:  2016-06-30       Impact factor: 79.321

Review 8.  Pulmonary embolism An update.

Authors:  Steven Doherty
Journal:  Aust Fam Physician       Date:  2017-11

Review 9.  Pulmonary embolism in the elderly: a review on clinical, instrumental and laboratory presentation.

Authors:  Luca Masotti; Patrick Ray; Marc Righini; Gregoire Le Gal; Fabio Antonelli; Giancarlo Landini; Roberto Cappelli; Domenico Prisco; Paola Rottoli
Journal:  Vasc Health Risk Manag       Date:  2008

10.  CT pulmonary angiography in patients with acute or chronic renal insufficiency: Evaluation of a low dose contrast material protocol.

Authors:  Mathias Meyer; Holger Haubenreisser; Christoph Schabel; Christianne Leidecker; Bernhard Schmidt; Stefan O Schoenberg; Thomas Henzler
Journal:  Sci Rep       Date:  2018-01-31       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.